Evommune, Inc. (EVMN) Stock
EVMN has an Alpha Score of 18 out of 100 (poor), computed on Nov 6, 2026 from 2 of 4 sub-scores. 2 of the hedge funds AlphaScala tracks reported EVMN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $19.07M.
What is EVMN's Alpha Score?
How it works →Alpha Score of 18 reflects poor overall profile with poor momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own EVMN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 1.44M | $19.07M | +3823% |
| Citadel Ken Griffin | 11K | $142.5K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are EVMN's key statistics?
Key statistics as of Nov 9, 2026
How does EVMN's valuation compare with the Healthcare sector?
| Metric | EVMN | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -606.20% | 3.60% | 175 |
| Return on equity | -46.76% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
EVMN price chart
Powered by TradingViewWhat does Evommune, Inc. do?
Evommune, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for immune-mediated chronic inflammatory diseases. Founded in 2020 and headquartered in Palo Alto, California, Evommune aims to create innovative treatments that address major unmet medical needs in conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company’s product candidates, EVO756 and EVO301, are currently in Phase 2 clinical trials, targeting both symptomatic relief and the underlying drivers of chronic inflammation. By leveraging advanced scientific research and a seasoned management team with deep expertise in immunology and drug development, Evommune, Inc. is positioned to contribute meaningfully to the rapidly evolving biopharmaceutical landscape. As a publicly listed entity, the company provides investors access to a specialized segment of the healthcare sector, reflecting broader investor interest in innovative biotech firms addressing chronic disease burden.